Verastem (VSTM) said Friday that two-year median follow-up data from a phase 2 trial of the Avmapki and Fakzynja combination therapy showed durable response with sustained clinical benefits across multiple efficacy measures in patients with recurrent low-grade serous ovarian cancer.
The company said analysis of efficacy measures, such as median duration of response and median progression free survival, at 24.9 months were consistent with the primary analysis done 13 months earlier.
Verastem said the combination therapy also continued to show a well-tolerated safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments